Review

Liver transplantation in the management of perihilar cholangiocarcinoma

Aliya F Gulamhusein

Division of Gastroenterology & Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA

Search for more papers by this author

William Sanchez

*Author for correspondence:

E-mail Address: sanchez.william@mayo.edu

Division of Gastroenterology & Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA

Search for more papers by this author

Published Online:6 Nov 2015https://doi.org/10.2217/hep.15.30

View article

Abstract

Cholangiocarcinoma (CCA) is the second most common primary hepatic neoplasm and accounts for 10–20% of hepatobiliary cancer-related deaths. The prognosis of patients with CCA is poor with 5-year survival rates of 10%, partially due to the limited effective treatment options that exist for this disease. In this review, we discuss the evolving role of liver transplantation in the management of patients with perihilar CCA (pCCA). We specifically discuss the Mayo Clinic protocol of neoadjuvant chemoradiation followed by liver transplantation in selected patients with pCCA and describe pretransplant, peritransplant, and post-transplant considerations and challenges with this approach. Finally, we review local, national and international outcomes and discuss future directions in optimizing this treatment strategy for patients who otherwise have few therapeutic options and limited survival.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 Khan SA, Davidson BR, Goldin RD et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 61(12), 1657–1669 (2012).Crossref, Medline, CAS, Google Scholar
2 Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncology 66(3), 167–179 (2004).Crossref, Medline, Google Scholar
3 Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am. J. Gastroenterol. 99(3), 523–526 (2004).Crossref, Medline, Google Scholar
4 Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145(6), 1215–1229 (2013).Crossref, Medline, CAS, Google Scholar
5 Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas. Gastroenterology 136(4), 1134–1144 (2009).Crossref, Medline, Google Scholar
6 Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 8(9), 512–522 (2011).Crossref, Medline, Google Scholar
7 Deoliveira ML, Cunningham SC, Cameron JL et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann. Surg. 245(5), 755–762 (2007).Crossref, Medline, Google Scholar
8 Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin. Gastroenterol. Hepatol. 11(1), 13–21, e11; quiz e13–e14 (2013).Crossref, Medline, Google Scholar
9 Jarnagin WR. Cholangiocarcinoma of the extrahepatic bile ducts. Semin. Surg. Oncol. 19(2), 156–176 (2000).Crossref, Medline, CAS, Google Scholar
10 Rea DJ, Munoz-Juarez M, Farnell MB et al. Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch. Surg. 139(5), 514–523, discussion 523–515 (2004).Crossref, Medline, Google Scholar
11 Petrowsky H, Hong JC. Current surgical management of hilar and intrahepatic cholangiocarcinoma: the role of resection and orthotopic liver transplantation. Transplant. Proc. 41(10), 4023–4035 (2009).Crossref, Medline, CAS, Google Scholar
12 Ito F, Cho CS, Rikkers LF, Weber SM. Hilar cholangiocarcinoma: current management. Ann. Surg. 250(2), 210–218 (2009).Crossref, Medline, Google Scholar
13 Lee SY, Cherqui D. Operative management of cholangiocarcinoma. Semin. Liver Dis. 33(3), 248–261 (2013).Crossref, Medline, Google Scholar
14 Farley DR, Weaver AL, Nagorney DM. ‘Natural history’ of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin. Proc. 70(5), 425–429 (1995).Crossref, Medline, CAS, Google Scholar
15 Kondo S, Hirano S, Ambo Y et al. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospective study. Ann. Surg. 240(1), 95–101 (2004).Crossref, Medline, Google Scholar
16 Pichlmayr R, Weimann A, Klempnauer J et al. Surgical treatment in proximal bile duct cancer. A single-center experience. Ann. Surg. 224(5), 628–638 (1996).Crossref, Medline, CAS, Google Scholar
17 Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann. Surg. 230(5), 663–671 (1999).Crossref, Medline, CAS, Google Scholar
18 Iwatsuki S, Todo S, Marsh JW et al. Treatment of hilar cholangiocarcinoma (klatskin tumors) with hepatic resection or transplantation. J. Am. Coll. Surg. 187(4), 358–364 (1998).Crossref, Medline, CAS, Google Scholar
19 Jang JY, Kim SW, Park DJ et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann. Surg. 241(1), 77–84 (2005).Crossref, Medline, Google Scholar
20 Todoroki T, Kawamoto T, Koike N et al. Radical resection of hilar bile duct carcinoma and predictors of survival. Br. J. Surg. 87(3), 306–313 (2000).Crossref, Medline, CAS, Google Scholar
21 Jarnagin WR, Fong Y, Dematteo RP et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann. Surg. 234(4), 507–517, discussion 517–509 (2001).Crossref, Medline, CAS, Google Scholar
22 Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch. Surg. 130(3), 270–276 (1995).Crossref, Medline, CAS, Google Scholar
23 Silva MA, Tekin K, Aytekin F, Bramhall SR, Buckels JA, Mirza DF. Surgery for hilar cholangiocarcinoma: a 10 year experience of a tertiary referral centre in the UK. Eur. J. Surg. Oncol. 31(5), 533–539 (2005).Crossref, Medline, CAS, Google Scholar
24 Li H, Qin Y, Cui Y, Chen H, Hao X, Li Q. Analysis of the surgical outcome and prognostic factors for hilar cholangiocarcinoma: a Chinese experience. Dig. Surg. 28(3), 226–231 (2011).Crossref, Medline, Google Scholar
25 Saxena A, Chua TC, Chu FC, Morris DL. Improved outcomes after aggressive surgical resection of hilar cholangiocarcinoma: a critical analysis of recurrence and survival. Am. J. Surg. 202(3), 310–320 (2011).Crossref, Medline, Google Scholar
26 Regimbeau JM, Fuks D, Le Treut YP et al. Surgery for hilar cholangiocarcinoma: a multi-institutional update on practice and outcome by the AFC-HC Study Group. J. Gastrointest. Surg. 15(3), 480–488 (2011).Crossref, Medline, Google Scholar
27 Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 69(8), 1633–1637 (2000).Crossref, Medline, CAS, Google Scholar
28 Brandsaeter B, Isoniemi H, Broome U et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J. Hepatol. 40(5), 815–822 (2004).Crossref, Medline, CAS, Google Scholar
29 Robles R, Figueras J, Turrion VS et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann. Surg. 239(2), 265–271 (2004).Crossref, Medline, Google Scholar
30 Ghali P, Marotta PJ, Yoshida EM et al. Liver transplantation for incidental cholangiocarcinoma: analysis of the canadian experience. Liver Transpl. 11(11), 1412–1416 (2005).Crossref, Medline, Google Scholar
31 Alessiani M, Tzakis A, Todo S, Demetris AJ, Fung JJ, Starzl TE. Assessment of five-year experience with abdominal organ cluster transplantation. J. Am. Coll. Surg. 180(1), 1–9 (1995).Medline, CAS, Google Scholar
32 Cosgrove ND, Al-Osaimi AM, Sanoff HK et al. Photodynamic therapy provides local control of cholangiocarcinoma in patients awaiting liver transplantation. Am. J. Transplant. 14(2), 466–471 (2014).Crossref, Medline, CAS, Google Scholar
33 Shimoda M, Farmer DG, Colquhoun SD et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl. 7(12), 1023–1033 (2001).Crossref, Medline, CAS, Google Scholar
34 Foo ML, Gunderson LL, Bender CE, Buskirk SJ. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 39(4), 929–935 (1997).Crossref, Medline, CAS, Google Scholar
35 Alden ME, Mohiuddin M. The impact of radiation dose in combined external beam and intraluminal ir-192 brachytherapy for bile duct cancer. Int. J. Radiat. Oncol. Biol. Phys. 28(4), 945–951 (1994).Crossref, Medline, CAS, Google Scholar
36 Sudan D, Deroover A, Chinnakotla S et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am. J. Transplant. 2(8), 774–779 (2002).Crossref, Medline, Google Scholar
37 Sio TT, Martenson JA, Jr., Haddock MG et al. Outcome of transplant-fallout patients with unresectable cholangiocarcinoma. Am. J. Clin. Oncol., (2014).• In patients who fall out of a transplant protocol, survival is similar to those with locally advanced or metatstatic disease.Medline, Google Scholar
38 Darwish Murad S, Kim WR, Therneau T et al. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology 56(3), 972–981 (2012).• Predictors of protocol dropout include elevated CA-19-9, large mass, malignant histology and high MELD and predictors of recurrence post-transplant include elevated CA-19-9, portal vein encasement and residual tumor on explant.Crossref, Medline, Google Scholar
39 Rea DJ, Heimbach JK, Rosen CB et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann. Surg. 242(3), 451–458, discussion 458–461 (2005).• Among candidates for surgical therapy, recurrence-free survival is significantly higher in patients with perihilar cholangiocarcinoma (pCCA) having neoadjuvant chemoradiation and OLT compared with those with surgical resection.Crossref, Medline, Google Scholar
40 Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl. Int. 23(7), 692–697 (2010).Crossref, Medline, Google Scholar
41 Sirica AE, Gores GJ. Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. Hepatology 59(6), 2397–2402 (2014).Crossref, Medline, Google Scholar
42 Blechacz BR, Sanchez W, Gores GJ. A conceptual proposal for staging ductal cholangiocarcinoma. Curr. Opin. Gastroenterol. 25(3), 238–239 (2009).Crossref, Medline, Google Scholar
43 Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48(1), 308–321 (2008).Crossref, Medline, CAS, Google Scholar
44 Rizvi S, Gores GJ. Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion 89(3), 216–224 (2014).Crossref, Medline, CAS, Google Scholar
45 Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD. The value of serum CA 19–9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig. Dis. Sci. 50(9), 1734–1740 (2005).Crossref, Medline, CAS, Google Scholar
46 Sinakos E, Saenger AK, Keach J, Kim WR, Lindor KD. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19–9 do not have cholangiocarcinoma. Clin. Gastroenterol. Hepatol. 9(5), 434–439, e431 (2011).Crossref, Medline, CAS, Google Scholar
47 Patel AH, Harnois DM, Klee GG, Larusso NF, Gores GJ. The utility of ca 19–9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am. J. Gastroenterol. 95(1), 204–207 (2000).Crossref, Medline, CAS, Google Scholar
48 Juntermanns B, Radunz S, Heuer M et al. Tumor markers as a diagnostic key for hilar cholangiocarcinoma. Eur. J. Med. Res. 15(8), 357–361 (2010).Crossref, Medline, CAS, Google Scholar
49 Ruys AT, Van Beem BE, Engelbrecht MR, Bipat S, Stoker J, Van Gulik TM. Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis. Br. J. Radiol. 85(1017), 1255–1262 (2012).Crossref, Medline, CAS, Google Scholar
50 Lopera JE, Soto JA, Munera F. Malignant hilar and perihilar biliary obstruction: use of MR cholangiography to define the extent of biliary ductal involvement and plan percutaneous interventions. Radiology 220(1), 90–96 (2001).Crossref, Medline, CAS, Google Scholar
51 Manfredi R, Barbaro B, Masselli G, Vecchioli A, Marano P. Magnetic resonance imaging of cholangiocarcinoma. Semin. Liver Dis. 24(2), 155–164 (2004).Crossref, Medline, Google Scholar
52 Masselli G, Manfredi R, Vecchioli A, Gualdi G. MR imaging and MR cholangiopancreatography in the preoperative evaluation of hilar cholangiocarcinoma: correlation with surgical and pathologic findings. Eur. Radiol. 18(10), 2213–2221 (2008).Crossref, Medline, Google Scholar
53 Vogl TJ, Schwarz WO, Heller M et al. Staging of klatskin tumours (hilar cholangiocarcinomas): comparison of MR cholangiography, MR imaging, and endoscopic retrograde cholangiography. Eur. Radiol. 16(10), 2317–2325 (2006).Crossref, Medline, Google Scholar
54 Barr Fritcher EG, Kipp BR, Slezak JM et al. Correlating routine cytology, quantitative nuclear morphometry by digital image analysis, and genetic alterations by fluorescence in situ hybridization to assess the sensitivity of cytology for detecting pancreatobiliary tract malignancy. Am. J. Clin. Pathol. 128(2), 272–279 (2007).Crossref, Medline, Google Scholar
55 Gonda TA, Glick MP, Sethi A et al. Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures. Gastrointest. Endosc. 75(1), 74–79 (2012).Crossref, Medline, Google Scholar
56 Kipp BR, Stadheim LM, Halling SA et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am. J. Gastroenterol. 99(9), 1675–1681 (2004).Crossref, Medline, Google Scholar
57 Dehaan RD, Kipp BR, Smyrk TC, Abraham SC, Roberts LR, Halling KC. An assessment of chromosomal alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcinomas. Hum. Pathol. 38(3), 491–499 (2007).Crossref, Medline, CAS, Google Scholar
58 Barr Fritcher EG, Kipp BR, Voss JS et al. Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. Am. J. Gastroenterol. 106(11), 2023–2028 (2011).Crossref, Medline, Google Scholar
59 Barr Fritcher EG, Voss JS, Jenkins SM et al. Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19–9 predict risk of malignancy. Cancer Cytopathol. 121(12), 708–717 (2013).Crossref, Medline, Google Scholar
60 Levy MJ, Heimbach JK, Gores GJ. Endoscopic ultrasound staging of cholangiocarcinoma. Curr. Opin. Gastroenterol. 28(3), 244–252 (2012).Crossref, Medline, Google Scholar
61 Mohamadnejad M, Dewitt JM, Sherman S et al. Role of EUS for preoperative evaluation of cholangiocarcinoma: a large single-center experience. Gastrointest. Endosc. 73(1), 71–78 (2011).Crossref, Medline, Google Scholar
62 Heimbach JK, Sanchez W, Rosen CB, Gores GJ. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford) 13(5), 356–360 (2011).Crossref, Medline, Google Scholar
63 Gleeson FC, Rajan E, Levy MJ et al. EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest. Endosc. 67(3), 438–443 (2008).Crossref, Medline, Google Scholar
64 Rosen CB, Darwish Murad S, Heimbach JK, Nyberg SL, Nagorney DM, Gores GJ. Neoadjuvant therapy and liver transplantation for hilar cholangiocarcinoma: is pretreatment pathological confirmation of diagnosis necessary? J. Am. Coll. Surg. 215(1), 31–38, discussion 38–40 (2012).• Similar rates of residual CCA and post-transplant recurrence in patients with and without pretreatment pathologic confirmation.Crossref, Medline, Google Scholar
65 De Vreede I, Steers JL, Burch PA et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl. 6(3), 309–316 (2000).Crossref, Medline, CAS, Google Scholar
66 Negm AA, Schott A, Vonberg RP et al. Routine bile collection for microbiological analysis during cholangiography and its impact on the management of cholangitis. Gastrointest. Endosc. 72(2), 284–291 (2010).Crossref, Medline, Google Scholar
67 Gores GJ, Gish RG, Sudan D, Rosen CB. Model for end-stage liver disease (meld) exception for cholangiocarcinoma or biliary dysplasia. Liver Transpl. 12(12 Suppl. 3), S95–97 (2006).Crossref, Medline, Google Scholar
68 Darwish Murad S, Kim WR, Harnois DM et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 143(1), 88–98 e83; quiz e14 (2012).•• Large multicenter experience demonstrating 65% 5-year recurrence-free survival post liver transplant in patients with pCCA from 12 US centers.Crossref, Medline, Google Scholar
69 Gores GJ, Darwish Murad S, Heimbach JK, Rosen CB. Liver transplantation for perihilar cholangiocarcinoma. Dig. Dis. 31(1), 126–129 (2013).Crossref, Medline, Google Scholar
70 Mantel HT, Rosen CB, Heimbach JK et al. Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl. 13(10), 1372–1381 (2007).Crossref, Medline, Google Scholar
71 Duignan S, Maguire D, Ravichand CS et al. Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience. HPB (Oxford) 16(1), 91–98 (2014).Crossref, Medline, Google Scholar
72 Friman S, Foss A, Isoniemi H et al. Liver transplantation for cholangiocarcinoma: selection is essential for acceptable results. Scand. J. Gastroenterol. 46(3), 370–375 (2011).Crossref, Medline, Google Scholar
73 Hashimoto K, Miller CM. Liver transplantation for intrahepatic cholangiocarcinoma. J. Hepatobiliary Pancreat. Sci. 22(2), 138–143 (2015).Crossref, Medline, Google Scholar
74 Sapisochin G, De Lope CR, Gastaca M et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study. Ann. Surg. 259(5), 944–952 (2014).Crossref, Medline, CAS, Google Scholar
75 Sapisochin G, Rodriguez De Lope C, Gastaca M et al. Very early’ intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients? Am. J. Transplant. 14(3), 660–667 (2014).Crossref, Medline, CAS, Google Scholar
76 Hong JC, Jones CM, Duffy JP et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch. Surg. 146(6), 683–689 (2011).•• Study demonstrating benefit of neoadjuvant therapy plus liver transplantation in patients with pCCA and iCCA.Crossref, Medline, Google Scholar
77 Rana A, Hong JC. Orthotopic liver transplantation in combination with neoadjuvant therapy: a new paradigm in the treatment of unresectable intrahepatic cholangiocarcinoma. Curr. Opin. Gastroenterol. 28(3), 258–265 (2012).Crossref, Medline, CAS, Google Scholar
78 Hong JC, Petrowsky H, Kaldas FM et al. Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma. J. Am. Coll. Surg. 212(4), 514–520, discussion 520–511 (2011).Crossref, Medline, Google Scholar
79 Kuhlmann JB, Blum HE. Locoregional therapy for cholangiocarcinoma. Curr. Opin. Gastroenterol. 29(3), 324–328 (2013).Crossref, Medline, Google Scholar
80 Welling TH, Feng M, Wan S et al. Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma. Liver Transpl. 20(1), 81–88 (2014).Crossref, Medline, Google Scholar

Vol. 2, No. 4

Metrics

Downloaded 41 times

History

Published online 6 November 2015

Published in print October 2015

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download